Makoto Naganuma1, Shinya Sugimoto2, Tomohiro Fukuda2, Keiichi Mitsuyama3, Taku Kobayashi4, Naoki Yoshimura5, Hidehisa Ohi6, Shinji Tanaka7, Akira Andoh8, Naoki Ohmiya9, Keiichiro Saigusa10, Takayuki Yamamoto11, Yuichi Morohoshi12, Hitoshi Ichikawa13, Katsuyoshi Matsuoka14,15, Tadakazu Hisamatsu16, Kenji Watanabe17, Shinta Mizuno2, Takayuki Abe18, Yasuo Suzuki19, Takanori Kanai2. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. nagamakoto@keio.jp. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. 3. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan. 4. Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. 5. Department of Internal Medicine, Division of IBD, Tokyo Yamate Medical Center, Tokyo, Japan. 6. Department of Gastroenterology, Imamura Hospital, Kagoshima, Japan. 7. Department of Endoscopy and Medicine, Hiroshima University Hospital, Hiroshima, Japan. 8. Department of Medicine, Shiga University of Medical Science, Otsu, Japan. 9. Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan. 10. Department of Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan. 11. IBD Center, Yokkaichi Hazu Medical Center, Yokkaichi, Japan. 12. Department of Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan. 13. Department of Gastroenterology, Tokai University Hachioji Hospital, Hachioji, Japan. 14. Department of Gastroenterology, Toho University Sakura Medical Center, Sakura, Japan. 15. Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan. 16. The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Japan. 17. Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan. 18. Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan. 19. Inflammatory Bowel Disease Center, Toho University Sakura Medical Center, Sakura, Japan.
Abstract
BACKGROUND: We recently reported the efficacy of indigo naturalis (IN) in patients with active ulcerative colitis (UC) in a randomized controlled trial (INDIGO study). However, few studies have been conducted to investigate whether IN is effective even in treatment-refractory cases, such as in those with steroid dependency and anti-TNF refractoriness. METHODS: In the INDIGO study, 86 patients with active UC were randomly assigned to an IN group (0.5-2.0 g daily) or placebo group. The rate of clinical response (CR), mucosal healing (MH), and change in fecal calprotectin (FCP) levels was compared between refractory [patients with steroid-dependent disease, previous use of anti-TNF-α, and concomitant use of immunomodulators (IM)] and non-refractory patients. We also analyzed factors predicting CR and MH at week 8. RESULTS: The rates of CR of IN group were significantly higher than placebo group, even in patients with steroid-dependent disease (p < 0.001), previous use of anti-TNF-α (p = 0.002), and concomitant use of IM (p = 0.013). The rates of MH in IN group were significantly higher than in placebo group in patients with steroid-dependent disease (p = 0.009). In the IN group, median FCP levels, at week 8, were significantly lower than baseline in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α (p < 0.001, respectively). Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. CONCLUSIONS: In a sub-analysis of data from a randomized placebo-controlled trial, we found that IN may be useful even in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α.
RCT Entities:
BACKGROUND: We recently reported the efficacy of indigo naturalis (IN) in patients with active ulcerative colitis (UC) in a randomized controlled trial (INDIGO study). However, few studies have been conducted to investigate whether IN is effective even in treatment-refractory cases, such as in those with steroid dependency and anti-TNF refractoriness. METHODS: In the INDIGO study, 86 patients with active UC were randomly assigned to an IN group (0.5-2.0 g daily) or placebo group. The rate of clinical response (CR), mucosal healing (MH), and change in fecal calprotectin (FCP) levels was compared between refractory [patients with steroid-dependent disease, previous use of anti-TNF-α, and concomitant use of immunomodulators (IM)] and non-refractory patients. We also analyzed factors predicting CR and MH at week 8. RESULTS: The rates of CR of IN group were significantly higher than placebo group, even in patients with steroid-dependent disease (p < 0.001), previous use of anti-TNF-α (p = 0.002), and concomitant use of IM (p = 0.013). The rates of MH in IN group were significantly higher than in placebo group in patients with steroid-dependent disease (p = 0.009). In the IN group, median FCP levels, at week 8, were significantly lower than baseline in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α (p < 0.001, respectively). Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. CONCLUSIONS: In a sub-analysis of data from a randomized placebo-controlled trial, we found that IN may be useful even in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α.
Authors: William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar Journal: Gastroenterology Date: 2011-11-04 Impact factor: 22.682
Authors: Axel Dignass; Rami Eliakim; Fernando Magro; Christian Maaser; Yehuda Chowers; Karel Geboes; Gerassimos Mantzaris; Walter Reinisch; Jean-Frederic Colombel; Severine Vermeire; Simon Travis; James O Lindsay; Gert Van Assche Journal: J Crohns Colitis Date: 2012-10-03 Impact factor: 9.071
Authors: Bruno Lamas; Mathias L Richard; Valentin Leducq; Hang-Phuong Pham; Marie-Laure Michel; Gregory Da Costa; Chantal Bridonneau; Sarah Jegou; Thomas W Hoffmann; Jane M Natividad; Loic Brot; Soraya Taleb; Aurélie Couturier-Maillard; Isabelle Nion-Larmurier; Fatiha Merabtene; Philippe Seksik; Anne Bourrier; Jacques Cosnes; Bernhard Ryffel; Laurent Beaugerie; Jean-Marie Launay; Philippe Langella; Ramnik J Xavier; Harry Sokol Journal: Nat Med Date: 2016-05-09 Impact factor: 53.440
Authors: William J Sandborn; Chinyu Su; Bruce E Sands; Geert R D'Haens; Séverine Vermeire; Stefan Schreiber; Silvio Danese; Brian G Feagan; Walter Reinisch; Wojciech Niezychowski; Gary Friedman; Nervin Lawendy; Dahong Yu; Deborah Woodworth; Arnab Mukherjee; Haiying Zhang; Paul Healey; Julian Panés Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245
Authors: S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer Journal: N Engl J Med Date: 1994-06-30 Impact factor: 91.245
Authors: William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts Journal: Gastroenterology Date: 2013-06-02 Impact factor: 22.682
Authors: Julie P Saiki; Johan Ol Andreasson; Kevin V Grimes; Lyn R Frumkin; Elvi Sanjines; Matthew G Davidson; K T Park; Berkeley Limketkai Journal: BMJ Open Gastroenterol Date: 2021-12